Eugene Kim Department of Surgery, Baylor College of Medicine, Houston
1 protocol

Danielle Hsu (Maiden name: Danielle M. Patterson) Department of Surgery, Baylor College of Medicine, USA
1 protocol

Jason M. Shohet
  • Department of Pediatrics, Baylor College of Medicine, USA
Research focus
  • Cancer biology
  • 1 Author merit


M.D., Ph.D. in Pathology, Boston University, School of Medicine, 1993

Current position

Associate Professor, Department of Pediatrics, Baylor College of Medicine, Houston, TX (2012- present)


Selected peer-reviewed publications

  1. Barone, G., A Tweddle, D., M Shohet, J., Chesler, L., Moreno, L., DJ Pearson, A. and Van Maerken, T. (2014). MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current drug targets 15(1): 114-123.
  2. Fan, Y., Cheng, J., Vasudevan, S., Dou, J., Zhang, H., Patel, R., Ma, I., Rojas, Y., Zhao, Y. and Yu, Y. (2013). USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell death & disease 4(10): e867.
  3. Ghosh, R., Singh, L. C., Shohet, J. M. and Gunaratne, P. H. (2013). A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials 34(3): 807-816.
  4. Barbieri, E., De Preter, K., Capasso, M., Chen, Z., Hsu, D. M., Tonini, G. P., Lefever, S., Hicks, J., Versteeg, R. and Pession, A. (2013). Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma. Cancer research.
  5. Barbieri, E., De Preter, K., Capasso, M., Johansson, P., Man, T.-K., Chen, Z., Stowers, P., Tonini, G. P., Speleman, F. and Shohet, J. M. (2013). A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk Neuroblastoma. PloS one 8(11): e79843.
  6. Hsu, D. M., Agarwal, S., Benham, A., Coarfa, C., Trahan, D. N., Chen, Z., Stowers, P. N., Courtney, A. N., Lakoma, A. and Barbieri, E. (2013). Expression of the G-CSF receptor, CD114, marks a novel, highly tumorigenic cell population in a neuroblastoma cell line. Cancer Research: canres. 4056.2012.
  7. Patterson, D. M., Shohet, J. M. and Kim, E. S. (2011). Pre-clinical Models of Pediatric Solid Tumors (Neuroblastoma) and their Use in Drug Discovery. Curr Postdoc Pharmacol (52)14.17.1-14.
  8. Shohet, J. M., Ghosh, R., Coarfa, C., Ludwig, A., Benham, A. L., Chen, Z., Patterson, D. M., Barbieri, E., Mestdagh, P. and Sikorski, D. N. (2011). A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer research 71(11): 3841-3851.
  9. Patterson, D. M., Shohet, J. M., Kim, E. S. (2011). Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol. Mar; Chapter 14: Unit 14.17.
  10. Shang, X., Vasudevan, S., Yu, Y., Ge, N., Ludwig, A., Wesson, C., Wang, K., Burlingame, S., Zhao, Y. and Rao, P. (2010). Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene 29(35): 4938-4946.
  11. Chen, Z., Lin, Y., Barbieri, E., Burlingame, S., Hicks, J., Ludwig, A. and Shohet, J. M. (2009). Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia (New York, NY) 11(8): 753.
  12. Wei, J. S., Song, Y. K., Durinck, S., Chen, Q.-R., Cheuk, A. T. C., Tsang, P., Zhang, Q., Thiele, C. J., Slack, A. and Shohet, J. (2008). The MYCN oncogene is a direct target of miR-34a. Oncogene 27(39): 5204-5213.
  13. Honeycutt, K., Chen, Z., Koster, M., Miers, M., Nuchtern, J., Hicks, J., Roop, D. and Shohet, J. (2006). Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. Oncogene 25(29): 4027-4032.
  14.  Barbieri, E., Mehta, P., Chen, Z., Zhang, L., Slack, A., Berg, S. and Shohet, J. M. (2006). MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Molecular cancer therapeutics 5(9): 2358-2365.
  15.  Slack, A., Chen, Z., Tonelli, R., Pule, M., Hunt, L., Pession, A. and Shohet, J. M. (2005). The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 102(3): 731-736.
1 Protocol published
In vivo Lineage-tracing Studies in a Cancer Stem Cell Population in Neuroblastoma
Authors:  Danielle M. Hsu, Jason M. Shohet and Eugene S. Kim, date: 04/20/2014, view: 8418, Q&A: 0
Tumors are comprised of heterogeneous subpopulations that may exhibit differing capacity for differentiation, self-renewal, and tumorigenicity. In vivo lineage-tracing studies are a powerful tool for defining the role of tumor ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.